Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X7XG
|
|||
| Former ID |
DAP001008
|
|||
| Drug Name |
Fusidic Acid
|
|||
| Synonyms |
FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
| MRSA infection [ICD-11: 1D01.0Y; ICD-10: A49.02; ICD-9: 41.12] | Phase 3 | [2] | ||
| Therapeutic Class |
Antibiotics
|
|||
| Company |
Leo Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H48O6
|
|||
| Canonical SMILES |
CC1C2CCC3(C(C2(CCC1O)C)C(CC4C3(CC(C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C
|
|||
| InChI |
1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
|
|||
| InChIKey |
IECPWNUMDGFDKC-MZJAQBGESA-N
|
|||
| CAS Number |
CAS 6990-06-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8919, 105658, 596017, 7979334, 10036127, 24702594, 24894729, 34666341, 46392987, 46505364, 46530473, 47206215, 47736747, 48416045, 49829529, 50959064, 53787526, 56314510, 56320723, 56320724, 57410087, 57654174, 74382570, 87895531, 93576759, 103511436, 109693457, 111610056, 124766024, 124801075, 127344473, 134338277, 134988294, 137004075, 139685296, 160965878, 164814155, 165235893, 175266845, 179230525, 184811991, 223715788, 225067369, 226413683, 241109573, 251916694, 251917933, 251970970, 252350108, 252402473
|
|||
| ChEBI ID |
CHEBI:29013
|
|||
| ADReCS Drug ID | BADD_D00980 | |||
| SuperDrug ATC ID |
D06AX01; D09AA02; J01XC01; S01AA13
|
|||
| SuperDrug CAS ID |
cas=006990063
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Streptococcus Elongation factor G (Stre-coc fusA) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. | |||
| REF 2 | Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis. 2011 Jun;52 Suppl 7:S513-9. | |||
| REF 3 | Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.